Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study

Adrian Bloor(The Christie NHS Foundation Trust), Rohini Radia(Nottingham University Hospitals NHS Trust), Gene Uenishi(University of Wisconsin–Madison), Igor I. Slukvin(University of Wisconsin–Madison), Kilian Kelly, Derek J. Hei, Maria Gilleece(Leeds Teaching Hospitals NHS Trust), Diana Drier(University of Wisconsin–Madison), Amit Patel(The Christie NHS Foundation Trust), Laurie S. Larson(University of Wisconsin–Madison), David T Yeung(South Australia Pathology), James E. Griffin(University Hospitals Bristol NHS Foundation Trust)
Nature Medicine
September 14, 2020
10.1038/s41591-020-1050-x
Cited by 289

Related Papers

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
|Blood|2018|208